PD-L1 expression in Triple Negative Breast Cancer: a study of an Iraqi population

Authors

DOI:

https://doi.org/10.20883/medical.e806

Keywords:

expression, PD-L1, triple negative, breast cancer

Abstract

Introduction. Breast cancer is the second most common cause of cancer death in women. Breast cancer awareness has increased due to mammography screening.

Aim. The study aims to evaluate the prevalence of the anti-programmed death-ligand 1 (PD-L1) expression in triple-negative breast cancer (TNBC) cases and to correlate it with clinicopathological parameters.

Material and methods. This retrospective study investigates 44 triple-negative breast cancer cases. PD-L1 expression was measured by an immunohistochemical technique using Dako kits, PD-L1 IHC 22C3 pharm Dx on 44 paraffin block samples from Duhok Municipal Laboratories. If the specimen has a combined positive score (CPS) of 10 or higher, it expresses PD-L1. Age groups, grades, types, stages, and lymph node status are studied.

Results. The mean age of the 44 patients was 47.7 years. 54.5% of the patients were in the middle age group, 63.6% were in grade III, 88.6% had invasive ductal carcinoma, and 75% were negative for PD-L1. 63.6% of the patients had the nuclear protein Ki67 (Ki-67) less than 20. 70.5% of the patients were in stage T2, and 45.5% had N1 lymph node status. There is a significant association between PD-L1 and Ki67. All patients with positive PD-L1 had Ki67 more than 20, while only 15.2% of the patients with negative PD-L1 had Ki67 more than 20.

Conclusion. Most TNBC patients are middle age, have grade III, and 75% have negative PD-L1. There is a significant association between PD-L1 and Ki-67. All patients with positive PD-L1 have Ki67 of more than 20.

Downloads

Download data is not yet available.

Author Biography

Gina James Keorges, Department of Pathology, College of medicine, University of Duhok, Kurdistan Region, Iraq

 

 

References

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi: 10.3322/caac.21332. DOI: https://doi.org/10.3322/caac.21332

Zhao Y, Wang R, Shi F, Wu J, Jiang F, Song Q. Diagnostic Efficacy of CT Examination on Early Detection of Lung Cancer during Pandemic of COVID-19. Diagnostics (Basel). 2022 Sep 26;12(10):2317. DOI: https://doi.org/10.3390/diagnostics12102317

Ge J, Zuo W, Chen Y, Shao Z, Yu K. The advance of adjuvant treatment for triple-negative breast cancer. Cancer Biol Med. 2021 Aug 27;19(2):187–201.

https://www.agilent.com/cs/library/usermanuals/public/29389_22c3_pharmdx_tnbc_interpretation_manual_kn355.pdf

Guan J, Lim KS, Mekhail T, Chang CC. Programmed Death Ligand-1 (PD-L1) expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 blockade. Arch Pathol Lab Med. 2017;141:851–861. DOI: https://doi.org/10.5858/arpa.2016-0361-RA

Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D, Bertucci F. Prognostic and predictive value of PD-L1 expression in breast cancer. Oncotarget. 2015;6:5449–5464. DOI: https://doi.org/10.18632/oncotarget.3216

Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20:2773–2782. DOI: https://doi.org/10.1158/1078-0432.CCR-13-2702

Baptista M, Sarian L, Derchain S, Pinto G, Vassallo J. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol. 2016;47:78–84. DOI: https://doi.org/10.1016/j.humpath.2015.09.006

Qin T, Zeng YD, Qin G, Xu F, Lu JB, Fang WF, Xue C, Zhan JH, Zhang XK, Zheng QF, Peng RJ, Yuan ZY, Zhang L, Wang SS. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget. 2015;6:33972–33981. DOI: https://doi.org/10.18632/oncotarget.5583

Ali HR, Glont SE, Blows FM, Provenzano E, Dawson SJ, Liu B, Hiller L, Dunn J, Poole CJ, Bowden S, Earl HM, Pharoah PD, Caldas C. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015;26:1488–1493. DOI: https://doi.org/10.1093/annonc/mdv192

Chierico L, Rizzello L, Guan L, Joseph AS, Lewis A, Battaglia G. The role of the two splice variants and extranuclear pathway on Ki-67 regulation in non-cancer and cancer cells. PLoS One. 2017 Feb 10;12(2):e0171815. DOI: https://doi.org/10.1371/journal.pone.0171815

Remnant L, Kochanova NY, Reid C, Cisneros-Soberanis F, Earnshaw WC. The intrinsically disorderly story of Ki-67. Open Biol. 2021 Aug;11(8):210120. DOI: https://doi.org/10.1098/rsob.210120

Hořejší B, Vinopal S, Sládková V, Dráberová E, Sulimenko V, Sulimenko T, Vosecká V, Philimonenko A, Hozák P, Katsetos CD, Dráber P. Nuclear γ-tubulin associates with nucleoli and interacts with tumor suppressor protein C53. J Cell Physiol. 2012 Jan;227(1):367-82. DOI: https://doi.org/10.1002/jcp.22772

Sales Gil R, Vagnarelli P. Ki-67: More Hidden behind a 'Classic Proliferation Marker'. Trends Biochem Sci. 2018 Oct;43(10):747-748. DOI: https://doi.org/10.1016/j.tibs.2018.08.004

https://www.agilent.com/cs/library/usermanuals/public/29389_22c3_pharmdx_tnbc_interpretation_manual_kn355.pdf.

Oakman C, Moretti E, Pacini G, Santarpia L, Di Leo A. Triple negative breast cancer: a heterogeneous subgroup defined by what it is not. European J Cancer. 2011;47:S370–S372. DOI: https://doi.org/10.1016/S0959-8049(11)70207-6

McCart Reed AE, Kutasovic JR, Vargas AC, Jayanthan J, Al-Murrani A, Reid LE, Chambers R, Da Silva L, Melville L, Evans E, Porter A, Papadimos D, Thompson EW, Lakhani SR, Simpson PT. An epithelial to mesenchymal transition programme does not usually drive the phenotype of invasive lobular carcinomas. J Pathol. 2016 Mar;238(4):489-94. DOI: https://doi.org/10.1002/path.4668

Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, Hortobagyi GN, Yee D, Smith IE, Chavez-MacGregor M, Nanda R, McArthur HL, Spring L, Reeder-Hayes KE, Ruddy KJ, Unger PS, Vinayak S, Irvin WJ Jr, Armaghani A, Danso MA, Dickson N, Turner SS, Perkins CL, Carey LA. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. J Clin Oncol. 2021 Dec 10;39(35):3938-3958. DOI: https://doi.org/10.1200/JCO.21.01374

Dill EA, Gru AA, Atkins KA, Friedman LA, Moore ME, Bullock TN, Cross JV, Dillon PM, Mills AM. PD-L1 expression and intratumoral heterogeneity across breast cancer subtypes and stages: an assessment of 245 primary and 40 metastatic tumors. Am J Surg Pathol. 2017;41:334–342. DOI: https://doi.org/10.1097/PAS.0000000000000780

Bae SB, Cho HD, Oh MH, Lee JH, Jang SH, Hong SA, Cho J, Kim SY, Han SW, Lee JE, Kim HJ, Lee HJ. Expression of Programmed Death Receptor Ligand 1 with high tumor- infiltrating lymphocytes is associated with better prognosis in breast cancer. J Breast Cancer. 2016;19:242–251. DOI: https://doi.org/10.4048/jbc.2016.19.3.242

Sun WY, Lee YK, Koo JS. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. J Transl Med. 2016;14:173. DOI: https://doi.org/10.1186/s12967-016-0925-6

Downloads

Published

2023-03-31

How to Cite

1.
Keorges GJ. PD-L1 expression in Triple Negative Breast Cancer: a study of an Iraqi population. JMS [Internet]. 2023 Mar. 31 [cited 2024 Jun. 16];92(1):e806. Available from: https://jms.ump.edu.pl/index.php/JMS/article/view/806

Issue

Section

Original Papers
Received 2023-01-18
Accepted 2023-03-27
Published 2023-03-31